Salvage use of tofacitinib in sarcoidosis patient with refractory multiorgan involvement
Main Article Content
Keywords
Sarcoidosis, Refractory disease, Tofacitinib
References
2. Bilgin B, Bilgin MK, Erol S, Celik G, Ozdemir Kumbasar O. Prognosis of sarcoidosis and factors affecting prognosis. Sarcoidosis Vasc Diffuse Lung Dis. 2023;40(4):e2023054.
3. Friedman MA, Le B, Stevens J, et al. Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study. Lung. 2021;199(2):147-53.
4. Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatol. 2020;2(2):106-9.
5. Kerkemeyer KL, Meah N, Sinclair RD. Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series. J Am Acad Dermatol. 2021;84(2):581-3.
6. Liu B, Yin H, Yang S, Lu L. Janus kinase inhibitor treatment improved both subcutaneous and pulmonary sarcoidosis in a patient with glaucoma. Clin Exp Dermatol. 2022;47(10):1868-70.
7. Toriola SL, Satnarine T, Zohara Z, et al. Recent Clinical Studies on the Effects of Tumor Necrosis Factor-Alpha (TNF-α) and Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Antibody Therapies in Refractory Cutaneous Sarcoidosis: A Systematic Review. Cureus. 2023;15(9):e44901.
8. Xu Q, Huang ZS, Liu QP, Wei JC. Tofacitinib for sarcoidosis, a new potential treatment. Int J Rheum Dis. 2022;25(11):1217-9.
9. Damsky W, Wang A, Kim DJ, et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun. 2022;13(1):3140.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
